Update of IGF-1 receptor inhibitor (ganitumab, dalotuzumab, cixutumumab, teprotumumab and figitumumab) effects on cancer therapy

Xiao Qu, Zhinan Wu, Wei Dong, Tiehong Zhang, Liguang Wang, Zhaofei Pang, Wei Ma and Jiajun Du _

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:29501-29518. https://doi.org/10.18632/oncotarget.15704

Metrics: PDF 2381 views  |   HTML 2924 views  |   ?  


Xiao Qu2,*, Zhinan Wu3,*, Wei Dong3, Tiehong Zhang1, Liguang Wang1, Zhaofei Pang2, Wei Ma3 and Jiajun Du3

1 Department of Oncology, Shandong Provincial Hospital Affiliated to Shandong University, Shandong, China

2 Institute of Oncology, Shandong Provincial Hospital Affiliated to Shandong University, Shandong, China

3 Department of Thoracic Surgery, Shandong Provincial Hospital Affiliated to Shandong University, Shandong, China

* These authors have contributed equally to this work

Correspondence to:

Jiajun Du, email:

Keywords: IGF-1R, combination chemotherapy, prognostic clinical trials, cancer treatment, curative effects

Received: June 29, 2016 Accepted: February 06, 2017 Published: February 25, 2017


Background: Prognostic studies of insulin-like growth factor-1 receptor(IGF-1R) inhibitors in cancer therapy had promising results in infratests, which exhibited that IGF-1R signalling was crucial in cancer cells growth. However, the conclusion of later clinical trials revealed a dim future for IGF-1R inhibitors to treat cancer. We conducted this analysis to figure out how IGF-1R inhibitors acted in clinical cancer therapy. Material and Methods: We searched up-to-date studies about the single agent of IGF-1R inhibitors or combination with other therapies in solid tumor. Five IGF-1R anti-agents were involved. The primary endpoint was progression-free survival (PFS). The secondary endpoint was overall survival (OS). Result: 17studies were enrolled. The results was not significant in overall survival (I2=37.1%, P=0.080, HR=1.08, 95% CI=0.97-1.21) and in progression-free survival (I2=0.0%, P=0.637, HR=1.05, 95% CI=0.98-1.12). OS for dalotuzumab, breast cancer, colorectal cancer, and PFS for prostate cancer even indicated harmful effects. Conclusion: So far, anti-IGF-1R mono-antibodies did not make significant differences in solid tumor prognosis. On the contrary, pessimistic effects were shown in the dalotuzumab, breast cancer, colorectal cancer and prostate cancer subgroups. Further studies of IGF-1R anti-agents were needed, but unwarranted in unselected patients by predictive biomarkers.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 15704